That's an excellent question.
The follow-on biologic products are referred to as “biosimilars” or, currently in the Health Canada legislation, “subsequent-entry biologics”. They are entering the marketplace in Canada. We now have five products approved in Canada. There are generics for some of the most expensive treatments. For rheumatoid arthritis, there's now a generic, Remicade. Traditional generic companies are moving into that space. We have approvals from companies like Sandoz and Apotex, which are the large generic companies in Canada.
In that space as well we also have traditional brand-name originator companies like Merck, Pfizer, and Eli Lilly that are also developing biosimilars. That is a new area. It's very exciting.
To your comment earlier about the enormous costs of biologic drugs and complex medicines, they are tremendous medicines. I think everyone would like to see more competition in that sphere. One of the main ways to do it is through promoting biosimilars and certainly our sector is doing that.
Separately, we have formed a new organization called the Biosimilars Board, whose sole purpose is to increase the utilization and acceptance of biosimilars in Canada.